Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.thromres.2020.08.009 | DOI Listing |
Pharmaceuticals (Basel)
November 2024
Independent Researcher, 5345 MT Oss, The Netherlands.
(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations.
View Article and Find Full Text PDFNeurol Sci
December 2024
Neuroradiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Via Amendola 2, Reggio Emilia, 42122, Italy.
Introduction: Pregnancy and postpartum are phases in the women's life where the thrombotic risk is increased both on the venous and on the arterial side.
Methods: We are presenting the case of a young woman at the third pregnancy, carried out without complications until delivery, whose postpartum was characterized by the occurrence of headache. Neuroimaging studies were performed, firstly brain computed tomography (CT) with CT Angiography and after brain Magnetic Resonance Imaging (MRI) with MR Angiography.
Am J Transl Res
November 2024
Reproductive Center, Hulunbeier People's Hospital Hailar, Hulunbuir 021000, Inner Mongolia, China.
Objective: To evaluate the efficacy of low-molecular-weight heparin (LMWH) in pregnant women with recurrent spontaneous abortion (RSA) and to investigate the correlation with changes in the gestational sac and embryo development, and miscarriage prevention as outcomes.
Methods: A retrospective analysis was conducted on 100 pregnant women with RSA treated at Hulunbeier People's Hospital between January 2022 and January 2023. Among them, 52 patients received LMWH therapy (observation group), while 48 received routine treatment (control group).
Am J Obstet Gynecol MFM
November 2024
Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China. Electronic address:
Objective: To assess the effectiveness and safety of low molecular weight heparins (LMWHs) on live birth rates and adverse pregnancy outcomes in individuals experiencing recurrent spontaneous abortion (RSA).
Data Sources: PubMed, Web of Science, the Cochrane Library, and Embase from database inception to July 1, 2024.
Study Eligibility Criteria: Eligible randomised controlled trials enrolled women with RSA who received LMWH, with a follow-up duration of at least 12 weeks.
Eur Heart J Case Rep
November 2024
Health New Zealand-Te Whatu Ora, Green Lane Cardiovascular Services/Cardiology Department, Auckland City Hospital, Park Road, Grafton, Auckland 1142, New Zealand.
Background: Unroofed coronary sinus (UCS) is a rare congenital anomaly and is usually found incidentally. While coronary sinus thrombosis (CST) can occur following instrumentation of the coronary sinus, spontaneous CST is a rare occurrence and only a few cases have been reported to date. The presence of both rare entities concurrently has not been reported previously.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!